Sarcopenia Market Size to grow at a CAGR of 2.36% till 2023

Sarcopenia Market Insights, Epidemiology and Market Forecast 2023 Report will provide an overview of the disease and global market size of the Sarcopenia with historical and foretasted epidemiological data for the prevalent cases of Sarcopenia from 2013 to 2023.

October 9, 2017 /MarketersMedia/ —

Diligent Market is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, Diligent Market provides cutting-edge data on Sarcopenia market and pipeline analysis and API intelligence, helping clients to quantify Sarcopenia market events and evaluate their impact on the valuation of its products, portfolios and companies.

As you know Sarcopenia is the progressive loss of skeletal muscle that comes with aging. Sarcopenia is multifactorial in cause. Most people begin to lose modest amounts of muscle mass after age 30, but the resulting loss of strength increases exponentially with age. Of the contributory factors relating to the development of sarcopenia inadequate protein intake, increased splanchnic extraction of amino acids, decreased muscular response to postprandial anabolic stimuli and vitamin D deficiency are directly related to nutrition.

"Sarcopenia Epidemiology Insights, 2023" report provides historical as well as forecasted epidemiology of Sarcopenia in the 7MM. Report covers the disease overview including pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

Table of Content of the report -
1. Report Introduction
2. Snapshot of Total Prevalent or Incident cases by 7 MM.
3. Executive Summary - Key Findings.
4. Sarcopenia Overview - Sarcopenia Definition, Pathophysiology, Symptoms and Etiology.
5. Risk Factors Associated with Sarcopenia
6. Disease Burden & Unmet Need in the Market
7. Epidemiology and Patient Populations
• Key Findings
• Key Sources used and Forecast Methodology
• Prevalent Cases and Incident Cases-2015-2025
• Prevalent & Incident Cases by Category-2015-2025
• Age-Specific Prevalent/ Incident Cases of Sarcopenia
• Sex-Specific Prevalent/Incident Cases of Sarcopenia
• Disease Type Specific Prevalent/Incident Cases of Sarcopenia
8. Prevalent & Incident Cases by 7 MM-2015-2025 - Sarcopenia Epidemiology of United States, UK, Germany, France, Spain, Italy and Japan.
9. Key Takeaways
10. Appendix
11. Report Methodology
12. Consulting Services
13. Disclaimer
14. About Us

Avail complete report of 40 pages @ https://www.diligentmarket.com/sarcopenia-epidemiology-insights-to-2023-13786-p.php

Diligent Market also provides a report on pipeline insights, "Sarcopenia -Pipeline Insights, 2017", report provides comprehensive insights of the ongoing therapeutic research and development across Sarcopenia. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Sarcopenia by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.
The report provides a snapshot of the pipeline development for the Sarcopenia. It covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Sarcopenia. The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information. Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Sarcopenia the report also covers the dormant and discontinued pipeline projects related to the Sarcopenia.

Check complete report @ https://www.diligentmarket.com/sarcopenia-pipeline-insights-2017-11524-p.php with key players like Dainippon Sumitomo Pharma Co., Ltd., GTX, Inc., MYOS Corporation, Regeneron Pharmaceuticals, Eli Lilly and Company, Endo Pharmaceuticals, Novartis AG, Biophytis, ARMGO Pharma, Celgene Cellular Therapeutics, and many more mentioned in it.

Diligent Market also provides a complete combination of market insights, epidemiology and market forecast till 2023 in one report. According to Diligent Market, the market size of Sarcopenia in 7 MM is estimated to be USD XX Million by 2023 at a CAGR of 2.36% for the forecast period i.e., 2013-2023. Also the prevalence cases in 7 MM are expected to increase and reach up to 42,969,489 cases by year 2023.

Report – “Sarcopenia-Market Insights, Epidemiology and Market Forecast-2023” will help in developing business strategies by understanding the trends shaping and driving the Sarcopenia market. It helps in organizing sales and marketing efforts by identifying the best opportunities for Sarcopenia in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. It helps in understanding the future market competition of Sarcopenia therapies in the 7MM and Insightful review of the key market drivers and barriers. The report provides historical as well as forecasted epidemiology of Sarcopenia in the 7MM. Report also gives regulatory scenario in major markets. The Report also covers the detailed historical and forecasted Sarcopenia market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2023.

Complete report with description, table of content and list of figures @ https://www.diligentmarket.com/sarcopenia-market-insights-epidemiology-and-market-forecast-2023-7-mm-13441-p.php

For further information or queries, please contact the Sales Team, Diligent Market at sales@DiligentMarket.com / irfan@DiligentMarket.com or call us at +91 750–707-8687.

Contact Info:
Name: Irfan Tamboli
Organization: Diligent Market
Phone: +91 750–707-8687

Source URL: https://marketersmedia.com/sarcopenia-market-size-to-grow-at-a-cagr-of-2-36-till-2023/246297

For more information, please visit https://www.diligentmarket.com/

Source: MarketersMedia

Release ID: 246297